ACM
DYN icon

Aster Capital Management’s Dyne Therapeutics DYN Stock Holding History

Aster Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-226
Closed -$2.36K – 952
2026
Q1 		$2.36K Sell
226
-4,084
-95% -$70.4K ﹤0.01% 750
2025
Q4 		$84.3K Buy
+4,310
New +$81.6K 0.04% 374
2025
Q2 		– Sell
-2,252
Closed -$30.6K – 1181
2025
Q1 		$30.6K Buy
2,252
+2,234
+12,411% +$32K 0.01% 915
2024
Q4 		$424 Buy
+18
New +$532 ﹤0.01% 1041

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Aster Capital Management's DYN Position: Q2 2026 in Review

Aster Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 226 shares — an estimated $2.36K sold.

Aster Capital Management first reported a position in DYN in Q4 2024 and held it in 4 quarters. The position peaked at $84.3K in Q4 2025. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Aster Capital Management reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 226 Dyne Therapeutics shares in Q2 2026, an estimated $2.36K.
  • Aster Capital Management first reported a position in Dyne Therapeutics in Q4 2024 and held it in 4 quarters.
  • Aster Capital Management's Dyne Therapeutics position peaked at $84.3K in Q4 2025.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.